Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2007 Nov 21.

Published in final edited form as: J Pharm Biomed Anal. 2007 Aug 2;45(2):295–303. doi: 10.1016/j.jpba.2007.07.026

Chromatograms of plasma samples obtained from a patient where: A. pre-dose; B. 6 h after the end of a 96-h infusion of 3.75g/m²/d (R,S)-IF. The observed peaks correspond to concentrations of: (S)-IF = 3.66 μg/ml; (R)-IF = 6.29 μg/ml; (S)-2-DCl-IF = 3.64 μg/ml; (R)-2-DCl-IF = 0.887 μg/ml; (S)-3-DCl-IF = 3.70 μg/ml and (R)-3-DCl-IF = 2.27 μg/ml. where: (1) = (S)-2-DCl-IF; (2) = (R)-2-DCL-IF; (3) = (S)-3-DClIF; (4) = (R)-3-DCl-IF.

Chromatograms of plasma samples obtained from a patient where: A. pre-dose; B. 6 h after the end of a 96-h infusion of 3.75g/m²/d (R,S)-IF. The observed peaks correspond to concentrations of: (S)-IF = 3.66 μg/ml; (R)-IF = 6.29 μg/ml; (S)-2-DCl-IF = 3.64 μg/ml; (R)-2-DCl-IF = 0.887 μg/ml; (S)-3-DCl-IF = 3.70 μg/ml and (R)-3-DCl-IF = 2.27 μg/ml. where: (1) = (S)-2-DCl-IF; (2) = (R)-2-DCL-IF; (3) = (S)-3-DClIF; (4) = (R)-3-DCl-IF.